L3VLUP
ProSign in

KYMR · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

KYMRAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • KYMR
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterKYMRAMGN
Q3 20202 holders, $8.3m16 holders, $16.3bn
Q4 20201 holders, $11m19 holders, $14.0bn
Q1 2021none listed holders, n.a.16 holders, $14.5bn
Q2 20211 holders, $1.8m23 holders, $13.8bn
Q3 20211 holders, $7.6m24 holders, $11.6bn
Q4 20211 holders, $171m21 holders, $10.4bn
Q1 20222 holders, $30m23 holders, $9.9bn
Q2 20221 holders, $2.0m28 holders, $9.7bn
Q3 20221 holders, $2.2m21 holders, $7.9bn
Q4 20223 holders, $226m24 holders, $9.3bn
Q1 20233 holders, $268m22 holders, $8.4bn
Q2 20231 holders, $2.5m26 holders, $7.4bn
Q3 20231 holders, $1.4m26 holders, $8.7bn
Q4 20233 holders, $150m24 holders, $8.4bn
Q1 20246 holders, $496m25 holders, $6.7bn
Q2 20244 holders, $343m20 holders, $8.0bn
Q3 20245 holders, $582m21 holders, $8.8bn
Q4 20246 holders, $536m20 holders, $8.2bn
Q1 20254 holders, $372m25 holders, $12.0bn
Q2 20255 holders, $615m20 holders, $10.2bn
Q3 20256 holders, $737m17 holders, $10.4bn
Q4 20257 holders, $1.7bn19 holders, $18.0bn
Q1 20268 holders, $2.1bn15 holders, $21.4bn
Q2 20268 holders, $3.0bn23 holders, $24.9bn
KYMR

Kymera Therapeutics Inc

Holders
8
Reported value
$3.0bn
Buyers
12
Sellers
13

Breadth -1 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
23
Reported value
$24.9bn
Buyers
19
Sellers
13

Breadth +6 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2026

Among the 25 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only KYMR (2)

Freestone Grove Partners LP, Holocene Advisors LP

Only AMGN (17)

Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, PDT Partners LLC, Squarepoint Ops LLC, Two Sigma Investments LP, Walleye Capital LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →